Page 6 - Pharma Sctors

Boehringer Ingelheim obtains ad-interim injunctions on 4 Indian pharma cos

The firms had launched generic versions of Boehringer's patent-protected drug Linagliptin, which is marketed under the brand name Trajenta

Near-term growth issues and cost pressure could impact Aurobindo Pharma

While valuations are now attractive, product approvals and progress on the injectable guidance are among key long-term term triggers

Paradeep Phosphates IPO gets 29% subscription; retail portion booked 57%

The initial public offer of Paradeep Phosphates was subscribed 29 per cent on the first day of subscription on Tuesday. The IPO received bids for 7,86,87,000 shares against 26,86,76,858 shares on offer, according to data available with NSE. The category for Retail Individual Investors (RIIs) was subscribed 57 per cent and the portion for non-institutional investors attracted 6 per cent subscription. The Initial Public Offer (IPO) has a fresh issue of equity shares aggregating to Rs 1,004 crore and an offer for sale of up to 11,85,07,493 equity shares. As part of the OFS, Zuari Maroc Phosphates Pvt Ltd (ZMPPL) will offload 60,18,493 equity shares and the government of India will sell up to 11,24,89,000 equity shares. The government will be offloading its entire 19.55 per cent stake in the company. Currently, ZMPPL holds 80.45 per cent stake and the government of India owns the rest 19.55 per cent stake in the company. The price range for the offer is at Rs 39-42 per share. On Fr

Strong specialty sales and volumes keep it sunny for Sun Pharma

Rerating on the cards; the domestic business is expected to outperform

Two Cipla promoters sell 20 mn shares; promoter group now holds 34.23%

Chairman Y K Hamied and Vice Chairman MK Hamied, who are non-executive directors and promoters, have sold 2,01,69,756 shares on Tuesday

Ipca Laboratories' PAT declines 26% to Rs 199.9 crore in December quarter

The company had posted a consolidated net profit of Rs 265.47 crore in the corresponding period last fiscal, Ipca Laboratories said in a regulatory filing

Brinton Pharma to launch generic version of anti-Covid pill Molnupiravir

The company will introduce it in the domestic market under the brand 'Molviton'

Moderna slump hits 50% from peak, erasing $98 billion value

Moderna's shares were pressured as coronavirus pills by Pfizer and Merck & Co recently received FDA authorisation

Adar Poonawalla picks up 20% stake in social media platform Wakau

Wakau offers a combination of mobile-first screen experience and short video content in entertainment and fashion domains

Moderna's booster raises antibody levels by 80 times against Omicron

The company said a two-dose course of its vaccine generated low neutralising antibodies against the Omicron variant

Drugmaker Biogen cuts the price tag on its Alzheimer's medicine in half

Biogen said that it will cut the wholesale acquisition cost of the drug by about 50 per cent next month

Natco board approves proposal to acquire US-based pharma company

The company's board has approved to acquire Dash Pharmaceuticals through one of its subsidiary units, it said

AstraZeneca blocks Advent's $7.6-bn buyout of Swedish Orphan Biovitrum

The UK drugmaker's opposition meant the offer fell short of the 90 per cent threshold needed for approval

Pharma stocks rally on buzz about new Covid variant, travel stocks sink

Huge gains for Cipla, Alkem Labs and Dr Lal Path, even as IndiGo, Chalet Hotels and IHC tank

BSE Healthcare index up 2%; Cipla, Alkem, Dr.Reddy's rally up to 8%

The pharma index had taken a breather over the past three months after displaying relative out-performance during CY20-21.

Cabinet secy-led panel to take call on more allocation to PLI pharma

The department has urged the top government panel to provide additional funds of around Rs 3,000 crore under the scheme for pharmaceutical medicines

Aurobindo Pharma Q2 net profit declines nearly 14% to Rs 697 crore

The drug firm on Monday reported a decline in its consolidated net profit

This SME pharma stock has zoomed 108% thus far in September

In past three months, Kwality Pharmaceuticals has zoomed 398 per cent, as compared to 12.8 per cent rise in the S&P BSE Sensex on the back of improved business outlook

ACC, Cipla: 66 stocks from Nifty 500 index are showing weakness on charts

Few pharma stocks are expected to weaken at higher levels.

Alembic Pharma sees domestic business growing in double digits this fiscal

Strong brand recall, an efficient sales force, a growing network of supportive doctors and timely product launches are the key catalysts for this business